Erectile Dysfunction |
ED; Erectile Disorder; Erectile Disorder (Impotence) |
Clinical Trial: Treatment of Erectile Dysfunction (ED) in Patients Treated for Prostate Cancer
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to see if there is a significant difference in erectile function between men treated with sildenafil (FDA approved drug for treatment of erectile dysfunction) versus placebo after radiation therapy (RT) plus neoadjuvant total androgen suppression (TAS) for prostate cancer and to determine if there is a significant difference in overall sexual function and satisfaction between men treated with sildenafil versus placebo.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Prostate Cancer | Drug: Sildenafil | Phase III |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title: Treatment of Erectile Dysfunction in Patients Treated for Prostate Cancer
Expected Total Enrollment: 332
Study start: September 2001; Expected completion: August 2004
This is a Phase III study. The study targets men with stage II and III prostate cancer recruited from the Radiation Therapy Oncology Group clinical trial (RTOG 99-10) treated with either 8 or 28 weeks of neoadjuvant TAS and RT with concurrent (8 week duration) TAS.
Eligibility
Ages Eligible for Study: 25 Years - 65 Years, Genders Eligible for Study: Male
Criteria
Location and Contact Information
Pennsylvania
American College of Radiology, Philadelphia, Pennsylvania, 19107, United States; Recruiting
More Information
Record last reviewed: January 2004
Last Updated: October 13, 2004
Record first received: January 2, 2004
ClinicalTrials.gov Identifier: NCT00075127
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


